SCHEMBL3518979

SCHEMBL3518979

CCOC(=O)CNC(=O)c1c(O)c(-c2cccs2)cc2nc(-c3ccc(F)c(F)c3)cnc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.36
SDHB P21912 1/20 0.35
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC3 O15379 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 2/20 0.34
KDM4E B2RXH2 4/20 0.34
HSD17B10 Q99714 2/20 0.34
HPGD P15428 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HIF1A Q16665 1/20 0.34
TNFRSF1A P19438 2/20 0.33
CASP1 P29466 1/20 0.33
GRIN2B Q13224 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519757 0.95 EGLN3 (0.38) EGLN3SDHBNPC1PKMRAB9A
SCHEMBL3519839 0.94 EGLN3 (0.38) EGLN3SDHBNPC1PKMRAB9A
SCHEMBL3519403 0.90 EGLN3 (0.40) EGLN3NPC1PKMRAB9ALMNA
SCHEMBL3756004 0.90 EGLN3 (0.42) EGLN3NPC1RAB9AMEN1KMT2A
SCHEMBL3520971 0.89 NPC1 (0.41) EGLN3SDHBNPC1RAB9AMEN1
SCHEMBL3519157 0.89 EGLN3 (0.47) EGLN3MEN1KMT2AKDM4EALDH1A1
SCHEMBL3526639 0.88 EGLN3 (0.36) EGLN3NPC1PKMRAB9ALMNA
SCHEMBL3520873 0.87 EGLN3 (0.40) EGLN3NPC1RAB9AMEN1KMT2A
SCHEMBL3519311 0.84 GAA (0.36) EGLN3NPC1PKMRAB9ALMNA
SCHEMBL3520062 0.83 EGLN3 (0.49) EGLN3NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885SDHB 17/4885NPC1 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.